Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its target price reduced by analysts at Wells Fargo & Company from $47.00 to $45.00 in a research report issued on Wednesday,Benzinga reports. Wells Fargo & Company‘s price target points to a potential upside of 77.80% from the company’s current price. Get Ultragenyx Pharmaceutical alerts:Read Our Latest Stock Analysis on Ultragenyx PharmaceuticalUltragenyx Pharmaceutical Price PerformanceNASDAQ:RARE traded down $0.50 during mid-day trading on Wednesday, hitting $25.31. Ultragenyx Pharmaceutical News RoundupHere are the key news stories impacting Ultragenyx Pharmaceutical this week:Ultragenyx Pharmaceutical Company Profile(Get Free Report)Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Featured StoriesReceive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.